ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease

Abstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF a...

Full description

Bibliographic Details
Main Authors: Julien Demagny, Aurélie Driss, Alain Stepanian, Nadia Anguel, Louis Affo, Damien Roux, Anoosha Habibi, Sandrine Benghezal, Sophie Capdenat, Paul Coppo, Françoise Driss, Agnès Veyradier
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
Online Access:https://doi.org/10.1002/rth2.12460
id doaj-7a6de7102e76435f88d5c97a5e44340a
record_format Article
spelling doaj-7a6de7102e76435f88d5c97a5e44340a2021-02-24T09:15:39ZengWileyResearch and Practice in Thrombosis and Haemostasis2475-03792021-01-015119720310.1002/rth2.12460ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell diseaseJulien Demagny0Aurélie Driss1Alain Stepanian2Nadia Anguel3Louis Affo4Damien Roux5Anoosha Habibi6Sandrine Benghezal7Sophie Capdenat8Paul Coppo9Françoise Driss10Agnès Veyradier11Service d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService d’HémaphérèseHôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService de Réanimation Médicale Hôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService de Médecine Interne Hôpital Louis MourierAP‐HP.NordUniversité de Paris Paris FranceService de Réanimation Médico‐Chirurgicale Hôpital Louis MourierAP‐HP.NordUniversité de Paris Paris FranceUnité des maladies du globule rougeHôpital Henri MondorAP‐HPUniversité Paris Est Créteil‐Val de marne Paris FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceCentre National de Référence des Microangiopathies Thrombotiques (CNR‐MAT) Département D’hématologie clinique Hôpital Saint AntoineAPHP.SUUniversité Pierre et Marie Curie Paris FranceService d’HémaphérèseHôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceAbstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF and its specific‐cleaving metalloprotease, ADAMTS13, in the vaso‐occlusive and thrombotic process of SCD. Patients/Methods We investigated the VWF antigen (Ag), ADAMTS13 activity, ADAMTS13 Ag and ADAMTS13 IgGs in a cohort of 65 patients with SCD prospectively enrolled in a 20‐month period from three centers. Patients were divided into two groups: an asymptomatic group (n = 30) with treated or untreated SCD at steady state, and a VOC/ACS group (n = 35) with SCD with VOC/ACS requiring either medical management or intensive care management for MOF. Results and Conclusions VWF:Ag levels were increased (median, 167 IU/dL; interquartile range [IQR], 124 ‐ 279), especially in patients with VOC SCD (227 IU/dL; IQR, 134‐305; P = .04), and positively correlated with inflammatory markers (P < .02). Median ADAMTS13 activity was normal (70 IU/dL; IQR, 60‐80), but 7 patients exhibited a partial deficiency between 25 and 45 IU/dL. ADAMTS13 activity/VWF:Ag ratio, however, did not change during VOC. Median ADAMTS13:Ag was slightly decreased (611 ng/mL; IQR, 504‐703) with no significant difference between groups. Surprisingly, ADAMTS13 IgGs were detected in 33 (51%) of our patients. We conclude that, in SCD, VWF:Ag and nonrelevant ADAMTS13 IgGs may reflect the severity of the inflammatory vasculopathy enhancing vaso‐occlusive and thrombotic complications.https://doi.org/10.1002/rth2.12460ADAMTS13sickle cell diseasethrombosisvaso‐occlusionvon Willebrand factor
collection DOAJ
language English
format Article
sources DOAJ
author Julien Demagny
Aurélie Driss
Alain Stepanian
Nadia Anguel
Louis Affo
Damien Roux
Anoosha Habibi
Sandrine Benghezal
Sophie Capdenat
Paul Coppo
Françoise Driss
Agnès Veyradier
spellingShingle Julien Demagny
Aurélie Driss
Alain Stepanian
Nadia Anguel
Louis Affo
Damien Roux
Anoosha Habibi
Sandrine Benghezal
Sophie Capdenat
Paul Coppo
Françoise Driss
Agnès Veyradier
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
Research and Practice in Thrombosis and Haemostasis
ADAMTS13
sickle cell disease
thrombosis
vaso‐occlusion
von Willebrand factor
author_facet Julien Demagny
Aurélie Driss
Alain Stepanian
Nadia Anguel
Louis Affo
Damien Roux
Anoosha Habibi
Sandrine Benghezal
Sophie Capdenat
Paul Coppo
Françoise Driss
Agnès Veyradier
author_sort Julien Demagny
title ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
title_short ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
title_full ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
title_fullStr ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
title_full_unstemmed ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
title_sort adamts13 and von willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
publisher Wiley
series Research and Practice in Thrombosis and Haemostasis
issn 2475-0379
publishDate 2021-01-01
description Abstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF and its specific‐cleaving metalloprotease, ADAMTS13, in the vaso‐occlusive and thrombotic process of SCD. Patients/Methods We investigated the VWF antigen (Ag), ADAMTS13 activity, ADAMTS13 Ag and ADAMTS13 IgGs in a cohort of 65 patients with SCD prospectively enrolled in a 20‐month period from three centers. Patients were divided into two groups: an asymptomatic group (n = 30) with treated or untreated SCD at steady state, and a VOC/ACS group (n = 35) with SCD with VOC/ACS requiring either medical management or intensive care management for MOF. Results and Conclusions VWF:Ag levels were increased (median, 167 IU/dL; interquartile range [IQR], 124 ‐ 279), especially in patients with VOC SCD (227 IU/dL; IQR, 134‐305; P = .04), and positively correlated with inflammatory markers (P < .02). Median ADAMTS13 activity was normal (70 IU/dL; IQR, 60‐80), but 7 patients exhibited a partial deficiency between 25 and 45 IU/dL. ADAMTS13 activity/VWF:Ag ratio, however, did not change during VOC. Median ADAMTS13:Ag was slightly decreased (611 ng/mL; IQR, 504‐703) with no significant difference between groups. Surprisingly, ADAMTS13 IgGs were detected in 33 (51%) of our patients. We conclude that, in SCD, VWF:Ag and nonrelevant ADAMTS13 IgGs may reflect the severity of the inflammatory vasculopathy enhancing vaso‐occlusive and thrombotic complications.
topic ADAMTS13
sickle cell disease
thrombosis
vaso‐occlusion
von Willebrand factor
url https://doi.org/10.1002/rth2.12460
work_keys_str_mv AT juliendemagny adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT aureliedriss adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT alainstepanian adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT nadiaanguel adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT louisaffo adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT damienroux adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT anooshahabibi adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT sandrinebenghezal adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT sophiecapdenat adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT paulcoppo adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT francoisedriss adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
AT agnesveyradier adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease
_version_ 1724253099372052480